These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37482935)

  • 1. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
    Irani YD; Hughes A; Kok CH; Clarson J; Yeung DT; Ross DM; Branford S; Hughes TP; Yong ASM
    Br J Haematol; 2023 Sep; 202(6):1127-1136. PubMed ID: 37482935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
    Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
    Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
    Front Immunol; 2018; 9():3152. PubMed ID: 30705677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
    Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
    Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
    Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
    Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
    Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
    Breccia M; Saglio G
    Br J Haematol; 2023 Sep; 202(6):1087-1088. PubMed ID: 37537862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment patterns and deep molecular response in chronic phase - chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study.
    Cortes J; Huynh L; Mendelson E; Brandt P; Dalal D; DerSarkissian M; Cortina D; Narkhede S; Sheng Duh M
    Leuk Lymphoma; 2020 Jan; 61(1):98-107. PubMed ID: 31409168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
    Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K
    Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
    Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
    Front Immunol; 2018; 9():2433. PubMed ID: 30405627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
    Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
    J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
    Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
    Cancer Sci; 2020 Aug; 111(8):2923-2934. PubMed ID: 32614159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
    Wang R; Cong Y; Li C; Zhang C; Lin H
    Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study.
    Nicolini FE; Etienne G; Dubruille V; Roy L; Huguet F; Legros L; Giraudier S; Coiteux V; Guerci-Bresler A; Lenain P; Cony-Makhoul P; Gardembas M; Hermet E; Rousselot P; Amé S; Gagnieu MC; Pivot C; Hayette S; Maguer-Satta V; Etienne M; Dulucq S; Rea D; Mahon FX
    Lancet Haematol; 2015 Jan; 2(1):e37-46. PubMed ID: 26687426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced perforin expression associated with dasatinib therapy in natural killer cells.
    Iriyama N; Takahashi H; Miura K; Uchino Y; Nakagawa M; Hatta Y; Takei M
    Leuk Res; 2018 May; 68():1-8. PubMed ID: 29494851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
    Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
    Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.